Deals and Data

Deals and Data

Sanofi inks deal with MannKind Corp to develop and market inhaled insulin therapy for adults with diabetes. (Reuters, 08/11/14)

FDA approves Merck’s prescription insomnia drug, Belsomra; alters action of brain chemical orexin, which helps regulate the sleep-wake cycle and helps keep people awake. (HealthDay, 08/13/14)

Ligand Pharmaceuticals to develop and commercialize four R&D programs based on its Captisol technology through collaboration with Avion Pharmaceuticals. (GEN News, 08/14/14)

FDA approves sixth indication for Genentech’s bevacizumab for treating patients with persistent, recurrent, or late-stage cervical cancer. (Medscape, 08/14/14)

AstraZeneca starts final-stage Phase III clinical trials for tralokinumab as treatment for severe asthma. (Reuters, 08/14/14)

The Scripps Research Institute maps molecular structure of Ebola and its antibodies using technology used to understand influenza and HIV. (U-T San Diego, 08/17/14)

Pfizer submits NDA for breast cancer drug palbociclib in combination with the aromatase inhibitor letrozole. (PharmaTimes Online, 08/19/14)

Novartis to invest in Israel’s Gamida Cell; conducting Phase I/II trials of NiCord to treat patients suffering from haematologic malignancies such as leukemia and lymphoma. (Reuters, 08/19/14)

SDSU publishes results of unusual expedition in which they did real-time DNA sequencing on species collected from the waters of the southern Line Islands in the central Pacific. (U-T San Diego, 08/19/14)

ViaCyte begins trial of stem cell-based diabetes therapy; insulin-producing cells from human embryonic stem cells. (U-T San Diego, 08/19/14)

FDA approves GSK’s fluticasone furoate inhalation powder as maintenance treatment for asthma in patients 12 years and older. (Medscape, 08/20/14)

Novartis inks deal with Global Alliance for TB Drug Development for compounds designed to tackle tuberculosis that have been discovered at NITD. (GEN News, 08/20/14)

Monsanto expects 2014 approval of genetically modified soybean seeds; resistant to broader range of stronger herbicides. (Inquisitr, 08/21/14)

Pfizer and Bristol-Myers Squibb’s blood thinner Eliquis approved to treat two types of dangerous blood clots. (Bloomberg Business Week, 08/21/14)

Celgene and Bristol-Myers Squibb collaborate to assess the safety, tolerability and preliminary efficacy of immuno-oncology drug Opdivo and Abraxane in phase I study. (Zacks, 08/21/14)

ViaCyte receives $20 million to advance its stem cell based therapy for type 1 diabetes into clinical trials. (U-T San Diego, 08/21/14)

Eli Lilly’s new psoriasis drug ixekizumab hits Phase III targets. (PharmaTimes Online, 08/21/14)

Illumina collaborates with AstraZeneca, Janssen Biotech, and Sanofi to develop a next-generation sequencing-based panel to serve as a universal companion diagnostic. (GenomeWeb, 08/22/14)

Merck and Advaxis test combination of Lm-LLO cancer immunotherapy and MK-3475 in advanced prostate cancer patients. (GEN News, 08/25/14)

FDA approves supplemental new drug application for GSK’s eltrombopag for patients with severe aplastic anemia who fail to respond adequately to immunosuppressive therapy. (Medscape, 08/26/14)